Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Men-United States, 2016-2018.
J Infect Dis
; 222(12): 2052-2060, 2020 11 13.
Article
em En
| MEDLINE
| ID: mdl-32504091
ABSTRACT
BACKGROUND:
In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011.METHODS:
The Vaccine Impact in Men study surveyed MSM and transgender women aged 18-26 years in 3 US cities during 2016-2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI).RESULTS:
Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at ageâ ≤18 years was 0.41 (CI, 0.24-0.57) and at ageâ >18 years was 0.82 (CI, 0.67-0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at ageâ ≤18 years orâ >18 years was 59% and 18%, respectively.CONCLUSIONS:
Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças do Ânus
/
Infecções por Papillomavirus
/
Vacinas contra Papillomavirus
/
Minorias Sexuais e de Gênero
/
Doenças da Boca
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article